Monks T J, Highet R J, Lau S S
University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957.
Mol Pharmacol. 1988 Oct;34(4):492-500.
2-Bromo-(diglutathion-S-yl)hydroquinone [2-Br-(diGSyl)HQ] causes severe necrosis of the proximal renal tubules in the rat, elevations in blood urea nitrogen (BUN) and increased urinary excretion of protein, glucose, and lactate dehydrogenase. In contrast, 2-Br-3-(GSyl)HQ, 2-Br-5-(GSyl)HQ, and 2-Br-6-(GSyl)HQ caused differentially less toxicity than the diglutathionyl conjugate. None of these conjugates had any apparent effect on liver pathology and serum glutamate-pyruvate transaminase remained within the normal range. Pretreatment of rats with probenecid, an organic anion transport inhibitor, offered only slight protection against 2-Br-(diGSyl)HQ-mediated elevations in BUN, proteinuria, or glucosuria. In contrast, quinine, an organic cation transport inhibitor, potentiated the nephrotoxicity of 2-Br-(di-GSyl)HQ. Thus, in contrast to other nephrotoxic sulfur conjugates, probenecid-sensitive organic ion transport systems do not contribute to the kidney-specific toxicity of 2-Br-(diGSyl)HQ. However, inhibition of renal gamma-glutamyl transpeptidase by AT-125 completely protected rats from the nephrotoxic effects of 2-Br-(diGSyl)HQ. Aminooxyacetic acid, an inhibitor of cysteine conjugate beta-lyase, caused a 20-25% decrease in 2-Br-(diGSyl)HQ-mediated elevations in BUN and urinary excretion parameters. The isomeric 35S conjugates covalently bound to rat kidney 10,000 x g homogenate in the order 2-Br-6-(GSyl)HQ greater than 2-Br-5-(GSyl)HQ greater than 2-Br-3-(GSyl)HQ greater than 2-Br-(diGSyl)HQ. AT-125 (0.4 mM) decreased covalent binding by 25%, 17%, 33%, and 28%, respectively. Aminooxyacetic acid (0.1 mM) inhibited covalent binding by 26%, 10%, 17%, and 17% respectively. Ascorbic acid (1.0 mM) inhibited covalent binding by 63%, 87%, 62%, and 28%, respectively, and this inhibition correlated, inversely, with the redox potential of the conjugates. Thus, the covalent binding is mediated preferentially by oxidation of the quinol moiety, although the formation of reactive thiols cannot be excluded. In addition, the initial conjugation of 2-BrHQ with GSH does not result in the formation of a less redox-active species. However, the subsequent addition of a second molecule of GSH results in the formation of a more redox-stable compound, which, paradoxically, enhances toxicity. The metabolism of 2-Br-(diGSyl)HQ by renal proximal tubular gamma-glutamyl transpeptidase and trans-membrane transport of the cysteine conjugate(s) followed by oxidation of the quinol moiety is probably responsible for the target organ toxicity of this compound.
2-溴-(双谷胱甘肽-S-基)对苯二酚[2-Br-(diGSyl)HQ]可导致大鼠近端肾小管严重坏死,血尿素氮(BUN)升高,蛋白质、葡萄糖和乳酸脱氢酶尿排泄增加。相比之下,2-Br-3-(GSyl)HQ、2-Br-5-(GSyl)HQ和2-Br-6-(GSyl)HQ的毒性比双谷胱甘肽共轭物小。这些共轭物对肝脏病理均无明显影响,血清谷丙转氨酶仍在正常范围内。用有机阴离子转运抑制剂丙磺舒预处理大鼠,对2-Br-(diGSyl)HQ介导的BUN升高、蛋白尿或糖尿仅有轻微保护作用。相比之下,有机阳离子转运抑制剂奎宁可增强2-Br-(di-GSyl)HQ的肾毒性。因此,与其他肾毒性硫共轭物不同,丙磺舒敏感的有机离子转运系统对2-Br-(diGSyl)HQ的肾脏特异性毒性没有贡献。然而,AT-125抑制肾γ-谷氨酰转肽酶可完全保护大鼠免受2-Br-(diGSyl)HQ的肾毒性作用。半胱氨酸共轭物β-裂解酶抑制剂氨氧乙酸可使2-Br-(diGSyl)HQ介导的BUN升高和尿排泄参数降低20%-25%。异构的35S共轭物与大鼠肾脏10000×g匀浆的共价结合顺序为2-Br-6-(GSyl)HQ>2-Br-5-(GSyl)HQ>2-Br-3-(GSyl)HQ>2-Br-(diGSyl)HQ。AT-125(0.4 mM)分别使共价结合减少25%、17%、33%和28%。氨氧乙酸(0.1 mM)分别抑制共价结合26%、10%、17%和17%。抗坏血酸(1.0 mM)分别抑制共价结合63%、87%、62%和28%,这种抑制与共轭物的氧化还原电位呈负相关。因此,共价结合优先由喹啉部分的氧化介导,尽管不能排除活性硫醇的形成。此外,2-BrHQ与GSH的初始共轭不会导致形成氧化还原活性较低的物种。然而,随后添加第二个GSH分子会导致形成更具氧化还原稳定性的化合物,这自相矛盾地增强了毒性。肾近端小管γ-谷氨酰转肽酶对2-Br-(diGSyl)HQ的代谢以及半胱氨酸共轭物的跨膜转运,随后喹啉部分的氧化可能是该化合物靶器官毒性的原因。